25I-NBOMe: Difference between revisions

Line 1:

{{~~Substance~~

~~|name=~~25I-NBOMe

~~|abbreviation=~~

~~|img-skel=File:25I-NBOMe2.png~~

~~|img-skel-width=351px~~

~~|img-3d=File:25I-NBOMe-3d.png~~

~~|img-3d--width=300~~

~~|dosage-note=~~

~~|dosage-method=sublingual~~

~~|dosage-threshold=50 - 250 µg~~

~~|dosage-light=200 - 600 µg~~

~~|dosage-common=500 - 800 µg~~

~~|dosage-strong=700 - 1500 µg~~

~~|dosage-heavy=~~

~~|duration-method=~~

~~|duration-total=6 - 10 hrs~~

~~|duration-onset=15 - 120 mins~~

~~|duration-coming-up=30 - 120 mins~~

~~|duration-peak=2 - 4 hrs~~

~~|duration-coming-down=1 - 4 hrs~~

~~|duration-after-effects=5 - 24 hrs~~

}}

'''25I-NBOMe''' ('''2C-I-NBOMe''') is a derivative of the [[Phenethylamines|substituted phenethylamine]] [[Psychedelics|psychedelic]] [[2C-I]], discovered in 2003 by Ralf Heim at the Free University of Berlin,<ref name="Ralf Heim PhD. (2010-02-28)">Ralf Heim PhD. (2010-02-28) "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts." | http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 (in German). diss.fu-berlin.de. Retrieved 2013-05-10.</ref> and subsequently investigated by a team at Purdue University led by [[David E. Nichols|David Nichols]].<ref name="Michael Robert Braden PhD. (2007)">Michael Robert Braden PhD. (2007). "Towards a biophysical understanding of hallucinogen action." | http://proquest.umi.com/pqdlink?Ver=1&Exp=01-23-2014&FMT=7&DID=1417800971&RQT=309&attempt=1&cfc=1 Purdue University. Retrieved 2012-08-08.</ref> The chemical had no history of human use prior to being sold online as a [[designer drug]] in 2010.

@@ Line 1: / Line 1: @@
-{{Substance
+{{SubstanceBox/25I-NBOMe}}
-|name=25I-NBOMe
-|abbreviation=
-|img-skel=File:25I-NBOMe2.png
-|img-skel-width=351px
-|img-3d=File:25I-NBOMe-3d.png
-|img-3d--width=300
-|dosage-note=
-|dosage-method=sublingual
-|dosage-threshold=50 - 250 µg
-|dosage-light=200 - 600 µg
-|dosage-common=500 - 800 µg
-|dosage-strong=700 - 1500 µg
-|dosage-heavy=
-|duration-method=
-|duration-total=6 - 10 hrs
-|duration-onset=15 - 120 mins
-|duration-coming-up=30 - 120 mins
-|duration-peak=2 - 4 hrs
-|duration-coming-down=1 - 4 hrs
-|duration-after-effects=5 - 24 hrs
-}}
 '''25I-NBOMe''' ('''2C-I-NBOMe''') is a derivative of the [[Phenethylamines|substituted phenethylamine]] [[Psychedelics|psychedelic]] [[2C-I]], discovered in 2003 by Ralf Heim at the Free University of Berlin,<ref name="Ralf Heim PhD. (2010-02-28)">Ralf Heim PhD. (2010-02-28) "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts." | http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 (in German). diss.fu-berlin.de. Retrieved 2013-05-10.</ref> and subsequently investigated by a team at Purdue University led by [[David E. Nichols|David Nichols]].<ref name="Michael Robert Braden PhD. (2007)">Michael Robert Braden PhD. (2007). "Towards a biophysical understanding of hallucinogen action." | http://proquest.umi.com/pqdlink?Ver=1&Exp=01-23-2014&FMT=7&DID=1417800971&RQT=309&attempt=1&cfc=1 Purdue University. Retrieved 2012-08-08.</ref> The chemical had no history of human use prior to being sold online as a [[designer drug]] in 2010.